NasdaqGS - Delayed Quote USD

Passage Bio, Inc. (PASG)

1.1900

+0.0600

(+5.31%)

At close: 4:00 PM EDT

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship award. The scholarship honors the legacy of Dr. Tachi Yamada, co-founder and former Chairman of the Passage Bio Board of Directors and is open to students enrolled in life sciences

GlobeNewswire 7 days ago

PASG
+5.31%
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy

Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 12 days ago

PASG
+5.31%
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Updated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CSF progranulin at six months post-treatment in the two patients with longest follow-upCompleted dosing of Cohort 1 (n=5) in upliFT-D trial; on track to deliver 6-month safety and biomarker data from Cohort 1 in 2H 2024Plan to continue studying Dose 1 in Cohort 2 of upliFT-D trial; expect to initiate dosing by the end of 1H 2024, as plannedInitiated regulatory process with FDA

GlobeNewswire 14 days ago

PASG
+5.31%
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, and Eden Fucci, senior vice president of technical operations, will participate in a virtual fireside chat at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024 at 9:

GlobeNewswire last month

PASG
+5.31%
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know

Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks 2 months ago

PASG
+5.31%
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program

$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or university Scholarship application deadline is April 26 for the initial award in the fall of 2024 PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the opening of its application process for its third

GlobeNewswire 2 months ago

PASG
+5.31%
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical trial site expansion into Europe and seven global sites now activatedPursuing new indications for PBFT02, including adult neurodegenerative diseases FTD-C9orf72, amyotrophic lateral sclerosis (ALS) and Alzheimer’s diseaseEnded 2023 with robust balance sheet sufficient to deliver meaningful clinical data; with cash runway into Q4 2025 PHILADEL

GlobeNewswire 2 months ago

PASG
+5.31%
Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care ConferenceFormat: Management will participate in a panel and investor meetingsDate: Tuesday, March 5, 2024Time: 10:30 a.m. ET Location: Boston, MA Leerink Partners Globa

GlobeNewswire 2 months ago

PASG
+5.31%
We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 3 months ago

PASG
+5.31%
7 Analyst-Backed Stocks With Promising 10-Bagger Potential

Stay on the Internet long enough – and it won’t take too long, believe me – and you’ll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns to outright conspiracy theories, the suits on Wall Street don’t always get the love from retail investors. Plus, they tend to be conservative for good reason. You don’t want to destroy your reputation by endorsing junk securities. That said, we’re all human. And humans love every now and then to specul

InvestorPlace 3 months ago

AGEN

PXLW

PASG
+5.31%
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:00 a.m. ET. A live webcast of the event will be available on the Investors & Med

GlobeNewswire 3 months ago

PASG
+5.31%
7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight

Playing in the field of nano-cap stocks is similar to the concept of stealing bases. In a tight baseball game, every advantage counts. Therefore, you might get the signal from the manager to steal a bag. You could end up being the hero or end up looking like a fool. It’s a binary proposition: high risk, high reward. And while advantages help break up a tight game, you also don’t want to give up cheap outs. That could put you in a serious disadvantage. And that’s why people seldom invest heavily

InvestorPlace 4 months ago

FPAY

JRSH

NSTG
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months post-treatmentDose 1 of PBFT02 was generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression Pipeline to focus on continued advancement of PBFT02 in FTD-GRN and explore PBFT02 in multiple additional adult neurodegenerative diseases Pursuing potential partners

GlobeNewswire 5 months ago

PASG
+5.31%
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passage Bio granted options to purchase 10,400 shares of common stock to this employee as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise pric

GlobeNewswire 6 months ago

PASG
+5.31%
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 2023Expect to report initial safety and biomarker data from Dose 3 patients in global Phase 1/2 Imagine-1 clinical trial for gangliosidosis (GM1) in mid-2024Robust balance sheet to support achievement of meaningful clinical milestones, with cash runway into Q4 2025 PHILA

GlobeNewswire 6 months ago

PASG
+5.31%
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET. A live webcast of the event will be available on

GlobeNewswire 6 months ago

PASG
+5.31%
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees. Passage Bio granted options to purchase 50,000 shares of common stock to these employees as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price

GlobeNewswire 7 months ago

PASG
+5.31%
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines Conference on Monday, October 2, 2023 at 5:00 p.m ET. A live webcast of the event will be available on the Investors & Media

GlobeNewswire 7 months ago

PASG
+5.31%
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 8 months ago

PASG
+5.31%
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of PBGM01 was able to achieve healthy control levels of CSF β-Gal activity and GM1 gangliosides, with response durable up to 12 months Treated first patient at Dose 3 in Imagine-1 clinical trial in July 2023; initial safety and biomarker data from Dose 3 patients expected by mid-20

GlobeNewswire 9 months ago

PASG
+5.31%

Performance Overview

Return	PASG	S&P 500
YTD	+17.82%	+11.24%
1-Year	+17.13%	+26.17%
3-Year	-91.40%	+26.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Passage Bio, Inc. (PASG)

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know

Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

7 Analyst-Backed Stocks With Promising 10-Bagger Potential

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Performance Overview